Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The rituxan hycela, rituxan mabthera (rituximab) market size has grown rapidly in recent years. It will grow from $3.43 billion in 2025 to $3.99 billion in 2026 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to increasing prevalence of non-hodgkin lymphoma, rising incidence of autoimmune diseases, expansion of biologic drug manufacturing, clinical validation of cd20-targeted therapies, wider hospital adoption of infusion therapies.

The rituxan hycela, rituxan mabthera (rituximab) market size is expected to see rapid growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to increasing penetration of biosimilar rituximab products, rising demand for outpatient oncology treatments, expansion of subcutaneous biologics, growing focus on cost-effective biologic therapies, increasing approvals in emerging markets. Major trends in the forecast period include increasing adoption of subcutaneous rituximab formulations, rising use of monoclonal antibody therapies, expansion of indications across oncology and autoimmune disorders, growing preference for shorter administration times, enhanced focus on biosimilar competition.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the Rituxan Hycela and Rituxan MabThera (rituximab) market in the future. Autoimmune diseases occur when the immune system mistakenly attacks healthy tissues, leading to chronic inflammation and organ damage. The prevalence of these diseases is increasing as healthcare providers and patients become more aware of the importance of early diagnosis, effective management, and access to targeted therapies to control disease progression and enhance quality of life. Rituxan Hycela and Rituxan MabThera (rituximab) are vital in addressing the rising prevalence of autoimmune diseases by controlling disease progression and improving patient outcomes through targeted B cell depletion. For example, in March 2023, the Society for Women’s Health Research, a US-based non-profit organization, estimated that autoimmune diseases affect between 23.5 million and 50 million people. Globally, the rates of autoimmune diseases are rising by 3 to 9 percent each year. As a result, the increasing prevalence of autoimmune diseases is driving the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market.

The rise in healthcare expenditure is expected to further fuel the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal healthcare, preventive services, and public health activities aimed at improving health outcomes within a specific time frame. This expenditure is increasing due to factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment models, and growing demand for healthcare services. Higher healthcare expenditure enhances access to advanced treatments like Rituxan Hycela and Rituxan MabThera (rituximab), thus driving the demand for effective therapies in oncology and autoimmune diseases. For instance, in May 2024, a report from the Office for National Statistics, a UK-based government agency, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of just 0.9% in 2022. As a result, rising healthcare expenditure is contributing to the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market.

Leading companies in the Rituxan Hycela and Rituxan MabThera (rituximab) market are prioritizing technological advancements, such as biosimilar anti-CD20 monoclonal antibodies, to enhance patient access, reduce treatment costs, and ensure clinical efficacy comparable to the original rituximab. A biosimilar monoclonal antibody is a biologic drug designed to closely mimic the reference rituximab (Rituxan/MabThera) in both structure and function, binding to the CD20 antigen on B cells to produce the same therapeutic effect while offering improved affordability and accessibility. For example, in July 2023, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, announced that its rituximab biosimilar, DRL_RI (proposed brand name ITUXREDI), was accepted by the U.S. FDA for review. This product replicates the same amino acid sequence, mechanism of action, and clinical outcomes as the reference rituximab, and is indicated for a range of conditions, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and vasculitis, thereby expanding patient access to vital therapies.

Major companies operating in the rituxan hycela, rituxan mabthera (rituximab) market are F. Hoffmann-La Roche AG (Genentech Inc.)

North America was the largest region in the rituxan hycela, rituxan mabthera (rituximab) market in 2025. The regions covered in the rituxan hycela, rituxan mabthera (rituximab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rituxan hycela, rituxan mabthera (rituximab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the rituxan hycela and rituxan mabthera market by raising costs of imported active pharmaceutical ingredients, biologic excipients, sterile packaging materials, and specialized manufacturing equipment. North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces cost pressure on contract manufacturing and exports. These tariffs are increasing production costs and affecting pricing and reimbursement strategies. At the same time, they are encouraging regional biologics manufacturing, local fill-finish investments, and supply chain diversification to support long-term market stability.

The rituxan hycela, rituxan mabthera (rituximab) market research report is one of a series of new reports that provides rituxan hycela, rituxan mabthera (rituximab) market statistics, including rituxan hycela, rituxan mabthera (rituximab) industry global market size, regional shares, competitors with a rituxan hycela, rituxan mabthera (rituximab) market share, detailed rituxan hycela, rituxan mabthera (rituximab) market segments, market trends and opportunities, and any further data you may need to thrive in the rituxan hycela, rituxan mabthera (rituximab) industry. This rituxan hycela, rituxan mabthera (rituximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rituxan Hycela and Rituxan MabThera (rituximab) are monoclonal antibody therapies that target CD20-positive B-cells. They are used to treat conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases like rheumatoid arthritis. Rituxan Hycela is a subcutaneous formulation, while Rituxan MabThera is administered intravenously.

The main types of Rituxan Hycela and Rituxan MabThera (rituximab) are available in 10 ml and 50 ml vials. The 10 ml vial of Rituxan Hycela is intended for patients who require a smaller dose of the medication. This dosage is typically suitable for those starting treatment or needing lower doses, allowing for personalized care. The administration routes include subcutaneous, intravenous, and parenteral, and the medication is distributed through hospital pharmacies, online pharmacies, and other outlets. It is used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions.

The rituxan hycela and rituxan mabthera (rituximab) market consists of sales of MabThera 1600 mg and ritunxan hycela (rituximab and hyaluronidase human injection). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.